Reaction

Intra-Abdominal Haemorrhage reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,359 reports · 54 co-occurring drugs

As of the last recalculation, Intra-Abdominal Haemorrhage appears in 2,359 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is FONDAPARINUX SODIUM (PRR 39.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Fondaparinux Sodium3639.840.0
Heparin Sodium3321.521.5
Dalteparin Sodium2117.717.7
Basiliximab2317.417.4
Enoxaparin Sodium9715.515.5
Anti-Thymocyte Globulin (Rabbit)1314.314.3
Emicizumab1913.713.7
Ganciclovir Sodium1512.612.6
Meperidine Hydrochloride1211.511.6
Micafungin Sodium1111.511.5
Ganciclovir1210.410.4
Warfarin Sodium5210.110.1
Alteplase1710.110.1
Prasugrel Hydrochloride119.69.6
Dabigatran Etexilate819.59.5
Phytonadione99.49.4
Dabigatran Etexilate Mesylate759.49.4
Midazolam Hydrochloride289.39.3
Warfarin1269.29.2
Norepinephrine119.19.1
Midazolam258.88.8
Norepinephrine Bitartrate148.68.6
Propofol327.87.8
Meropenem287.87.8
Levonorgestrel1637.67.6
Imatinib157.57.6
Calcium Gluconate107.37.4
Sorafenib166.86.8
Rivaroxaban1506.76.7
Goserelin106.66.6
Pegaspargase96.56.5
Misoprostol76.46.4
Dronedarone76.16.1
Imatinib Mesylate196.16.1
Rocuronium Bromide86.06.0
Remdesivir96.06.0
Cytarabine375.55.5
Entecavir75.35.3
Sunitinib Malate225.05.0
Lenvatinib184.94.9
Methoxy Polyethylene Glycol-Epoetin Beta64.84.8
Encorafenib54.54.5
Selexipag134.54.5
Apixaban334.44.4
Linezolid144.24.2
Blinatumomab43.43.4
Pazopanib Hydrochloride103.33.3
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose33.23.2
Atezolizumab143.23.2
Bosentan183.23.2
Romiplostim52.92.9
Trametinib82.92.9
Durvalumab52.22.2
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride72.02.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.